Trading involves risk
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
Trading involves risk
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
English (International)
Galapagos NV
Open
SectorHealthcare
28.08 -0.21
Overview
Share price change
24h
Min
27.78
Max
28.28
Income | -96M -202M |
|---|---|
Sales | 5.9M 71M |
Profit margin | -284.019 |
Employees | 704 |
Recommendations | Sell |
|---|---|
12 Months Forecast | -13.1% downside |
Market Cap | -26M 1.8B |
|---|---|
Previous open | 28.29 |
Previous close | 28.08 |
News Sentiment
By Acuity
100%
0%
352 / 374 Healthcare
Galapagos NV Chart
Past performance is not a reliable indicator of future results.
Related News
Galapagos NV Forecast
Price Target
By TipRanks
-13.1% downside
12 Months Forecast
Average 24.47 EUR -13.1%
High 27.9 EUR
Low 22 EUR
Based on 4 Wall Street analysts offering 12 month price targets forGalapagos NV - Dist in the last 3 months.
Sentiment
By Acuity
352 / 374 Healthcare
News Sentiment
Very Strong Bearish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Galapagos NV
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Live chat